No momento em que há a agressão tecidual e a defesa inata é deflagrada, mediadores químicos são liberados no local afetado. Esses mediadores podem ser de origem celular tais como CGRP, VEGF e TGFß. Os objetivos desta pesquisa foram avaliar a expressão e distribuição de CGRP, TGFß e VEGF na gengiva do primeiro molar inferior esquerdo de rato no 7 e 14 dias após a indução por ligadura; a expressão e distribuição de CGRP, TGFß e VEGF na gengiva do dente contralateral correspondente sem ligadura, no 7 e 14 dias, e se a indução da periodontite por ligadura no dente experimental provoca uma inflamação na gengiva do dente contralateral correspondente no 7 e 14 dias após a ligadura. Para o desenvolvimento deste trabalho foram selecionados 15 ratos Rattus Novergicus, Albinus, Wistar. O grupo experimental de 12 ratos foi dividido em 2 subgrupos compostos por 6 ratos cada um deles distribuídos da seguinte maneira: os do subgrupo A1 permaneceram com a ligadura no primeiro molar inferior esquerdo por 7 dias e foram sacrificados; os do subgrupo A-2 -permaneceram com a ligadura no primeiro molar inferior esquerdo por 14 dias e foram sacrificados. Outros três animais constituíram o grupo controle. Após o sacrifício dos 12 animais dos grupos experimentais e controle suas mandíbulas foram colocadas em ácido etilenodiaminotetracético (EDTA) neutro para sofrerem descalcificação. Então foram processadas para inclusão em parafina e os cortes histológicos foram corados pela hematoxilina-eosina e submetidos à técnica imunohistoquímica para imunomarcação de CGRP, VEGF e TGFß. Aos 7 dias de ligadura observou-se na lâmina própria gengival, epitélio juncional e epitélio oral, expressiva marcação para CGRP. A expressão de VEGF foi intensa na lamina própria e com pouca ou nenhuma marcação no epitélio oral e juncional. O TGFß apresentou pouca marcação na lâmina própria ou nenhuma marcação no epitélio oral e juncional. Aos 14 dias de ligadura houve expressiva marcação de CGRP na lâmina própria, epitélios oral e juncional. O VEGF e o TGFß apresentaram muita marcação na lâmina própria e pouca ou nenhuma marcação no epitélio oral e juncional. Na gengiva dos dentes contralaterais nos 7 e 14 dias houve pouca marcação do CGRP do TGFß na lâmina própria e muita marcação do VEGF. Na gengiva dos dentes controle observou-se muita marcação do CGRP no epitélio juncional e oral e na lâmina própria. O TGFß e o VEGF se expressaram muito pouco ou não se expressaram. Devido à marcação expressiva do VEGF na lâmina própria dos dentes contralaterais, permanece inconclusiva a adequação do uso dos dentes contralaterais nos estudos experimentais das doenças periodontais, embora a expressão de TGFß e CGRP tenham sido menores nestes dentes. A maior marcação do CGRP, VEGF e TGFß nos animais com 14 dias de ligadura do que aos 7 dias demonstra a progressão do processo inflamatório crônico, não se observando processo de reparação cicatricial. / At the time of the tissue aggression the innate defense is triggered and the chemical mediators are released in the affected site. These mediators may have cell origin as the CGRP, VEGF and TGFß. The aim of this research were to evaluate the expression and distribution of the CGRP, VEGF and TGFß in the gingiva of the lower left first molar of rats in the seven and fourteen days after the ligature for inflammation induction; to analyse the expression and distribution of the CGRP, VEGF and TGFß in the gingiva of the correspondent counter lateral tooth without ligature in the seven and fourteen days and if the induction of periodontitis causes gingival inflammation of the counter lateral tooth after seven and fourteen days after ligature. For the development of this work were selected fifteen Rattus Novergicus, Albinus,Wistar. The experimental group of 12 rats was divided into 2 groups consisting of 6 rats each distributed of the following manner: the subgroup A1 remained with ligature in the first molar and left for 7 days before the sacrificed and the subgroup A-2 remained with the ligature for 14 days before the sacrificed. Another 3 animals constituted the control group. After the sacrificed of the 12 experimental and 3 control animals were immersedin neutral ethylenidiaminetetracetic (EDTA) for the decalcification. Then were processed for paraffin embedding. The sections were stained with hematoxylin-eosin and submitted to immunohistochemical techniques to imunostaining for CGRP, VEGF and TGFß. At 7 days of ligature was observed in the gingival lamina propria, junctional epithelium and oral epithelium, strong staining for CGRP. The intensive expression of VEGF occur in the lamina propria and scarce or no staining in the oral and junctional epithelium. The TGFß shows scarce staining in the lamina propria and no staining in the oral and junctional epithelium. At the fourteen days of ligature we observed strong staining of CGRP in the lamina propria and oral and junctional epithelium. The VEGF and TGFß show strong staining in the lamina propria and scarce or no staining in the junctional and oral epithelium. At the gingival of the counterlateral teeth in the 7 and 14 days there was scarce staining for CGRP and TGFß in the lamina propria and strong staining to VEGF. In the gingival of couterlateral teeth there was strong staining to CGRP in the junctional and oral epithelium and lamina propria. The TGFß and VEGF show scarce or none staining. Because the strong staining of VEGF in the lamina propria of the counterlateral teeth remain inconclusive the adequacy of the use of the counterlateral teeth in the experimental studies of the periodontal diseases, though the expression of the TGFß and CGRP has been smaller in this teeth. The bigger staining of CGRP, VEGF and TGFß in the animals with 14 days of ligature than those 7 days shows the evolution of the chronic inflammation process. We dont observe the process of tissue healing.

Angiogênese é o termo utilizado para descrever o crescimento de novos vasos sanguíneos a partir dos já existentes. Vários estudos demonstraram a densidade microvascular (DMV) como um fator prognóstico nas leucemias, em particular, leucemia promielocítica aguda (LPA). Este subtipo de leucemia corresponde a cerca de 20 a 25% das leucemias mielóides agudas nos países latino-americanos e apresenta características clínicas, morfológicas e biológicas peculiares. A halofuginona (HF), originalmente descrita como um agente antifúngico apresenta capacidade de inibir o crescimento tumoral e formação de vasos em modelos animais de tumores sólidos. Estudos realizados por nosso grupo demonstraram que a HF inibiu a secreção do VEGF e a proliferação de linhagens celulares de LPA. Desta forma, o presente trabalho teve por objetivo determinar o potencial antiproliferativo e antiangiogênico da HF em um modelo experimental in vivo da LPA e avaliar os mecanismos subjacentes a sua ação. Primeiramente, a análise do ciclo celular em células NB4 tratadas com HF apresentou significativa diminuição da proliferação celular (2,093 ± 0,304 vs. 41,21 ± 3,25), juntamente com um aumento significativo da apoptose (12,53 ± 1,53 vs. 21,95 ± 0,79; p=0,0007). Por meio da técnica de Real Time Array foi possível identificar dois grupos de genes associados a apoptose celular diferencialmente expressos em células tratadas com HF: TNF, TNFRSF9, TNFTSF10B, CD40, FAS, CASP10, CASP8 e CASP3, sugerindo que a HF induz a via extrínseca de apoptose. A análise in vivo da HF foi realizada em camundongos NOD/SCID previamente irradiados e transplantados com células leucêmicas PML-RAR murinas. Camundongos tratados com HF, por 21 dias após o transplante não apresentaram remissão molecular, determinada pela amplificação do gene PML-RARA por PCR, porém foi observada menor infiltração leucêmica em relação aos camundongos não tratados (Leucócitos: 4,2 ± 3,89 vs. 20,6 ± 21,9; p<0.0001); Hemoglobina: 12,0 ± 1,40 vs. 9,6 ± 1,67; p<0.0001; e Plaquetas: 932,0 ± 122,5 vs. 552,0 ± 83,2; p<0.001 respectivamente) e um menor peso relativo do baço (0,006 vs. 0,012, p=0,0415). Ademais, a contagem diferencial e imunofenotipagem da medula óssea evidenciaram menor porcentagem de células mielóides imaturas (16,88 ± 6,27 vs. 44,06 ± 27,06). A HF também foi capaz de inibir a fosforilação de SMAD2 e consequentemente bloquear a via do TGF- em células NB4. No entanto, animais leucêmicos apresentaram menor nível sérico de TGF- em relação aos saudáveis e tratados (475,58 vs. 1.378,45/1.146,82 pg/mL; p<0,0001), sugerindo que o blasto leucêmico produz esta citocina e a diminuição de células leucêmicas resultou em diminuição dos níveis séricos de TGF-. A HF não aumentou a sobrevida dos animais leucêmicos e a elevação das enzimas hepáticas sugeriu que o tratamento foi hepatotóxico. Por fim, com relação à angiogênese, a análise da expressão gênica mostrou que o tratamento com HF inibiu a expressão de VEGF e EGF e o estudo por imunohistoquímica de seções da medula óssea evidenciou menor expressão VEGF (30 vs. 80%, p=0,0227), porém não houve diminuição da DMV. O conjunto desses resultados mostrou que a angiogênese é um importante alvo terapêutico na LPA, e que apesar da toxicidade, a HF apresenta potencial antileucêmico, tanto por conta de seus efeitos antiproliferativos e próapoptóticos, quanto por sua capacidade de inibir a produção de fatores próangiogênicos. / Angiogenesis is the term used to describe the growth of new blood vessels from the existing ones. Several studies have demonstrated the microvascular density (MVD) as a prognostic factor in leukemia, particularly acute promyelocytic leukemia (APL). This subtype of leukemia corresponds to 20-25% of acute myeloid leukemia in Latin America and presents clinical, morphological and biological peculiar characteristics. The halofuginone (HF) originally described as an antifungal agent has ability to inhibit tumor growth and vessel formation in animal models of solid tumors. Our group demonstrated that HF inhibits the VEGF secretion and cell proliferation in APL cell lineages. Thus, this study aimed to determine the antiproliferative and antiangiogenic potential of HF in an experimental model of APL in vivo and evaluate the mechanisms underlying its action. First, the cell cycle analysis in NB4 cells treated with HF showed a significant decrease in cell proliferation (2.093 ± 0.304 vs. 41.21 ± 3.25), along with a significant increase in apoptosis (12.53 ± 1.53 vs . 21.95 ± 0.79, p = 0.0007). Through Real Time Array it was possible to identify two groups of apoptosis associated genes differentially expressed in HF treated cells: TNF, TNFRSF9, TNFTSF10B, CD40, FAS, CASP10, CASP8 and CASP3, suggesting that HF induces apoptosis by extrinsic pathway. In vivo analysis of HF was performed in irradiated NOD/SCID mice transplanted with murine PML-RAR leukemic cells. Mice treated with HF for 21 days after transplantation showed no molecular remission as determined by amplification of PML-RARA gene by PCR, however minor leukemic infiltration was observed compared to untreated mice (leukocytes: 4.2 ± 3.89 vs . 20.6 ± 21.9, p <0.0001), hemoglobin: 12.0 ± 1.40 vs. 9.6 ± 1.67, p <0.0001, and Platelets: 932.0 ± 122.5 vs. 552.0 ± 83.2, p <0.001 respectively) and a lower relative weight of spleen (0.006 vs. 0.012, p = 0.0415). Furthermore, the differential count and immunophenotyping of bone marrow showed a lower percentage of immature myeloid cells (16.88 ± 6.27 vs. 44.06 ± 27.06). The HF was also able to inhibit the SMAD2 phosphorylation and consequently block the TGF- pathway in NB4 cells. However, leukemic animals presented lower serum TGF- compared to the healthy and treated (475.58 vs. 1378.45/1146.82 pg / mL, p <0.0001), suggesting that the leukemic blasts produces this cytokines and the decrease in leukemic cells resulted in decreased serum levels of TGF-. The HF did not increase the survival of leukemic animals and elevated liver enzymes suggested that the treatment was hepatotoxic. Finally, regarding angiogenesis, gene expression analysis showed that the HF treatment inhibited the expression of VEGF and EGF and the study by immunohistochemistry of sections of bone marrow showed less VEGF expression (30 vs. 80%, p = 0 0227), but there was no decrease in the MVD. Taken together, these results showed that angiogenesis is an important therapeutic target in APL, and despite the toxicity, HF has antileukemic potential, for both the antiproliferative and proapoptotic effects, and also for its ability to inhibit the production of proangiogenic factors.

Orientador: Albina Messias de Almeida Milani Altemani / Dissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Ciências Médicas / Made available in DSpace on 2018-08-17T21:55:29Z (GMT). No. of bitstreams: 1 Mello_MarcosFernandoSantos_M.pdf: 647246 bytes, checksum: 43815d880ab846eae0d6898832f1bc41 (MD5) Previous issue date: 2011 / Resumo: Metástase em linfonodo é um importante indicador prognóstico em cânceres de cabeça e pescoço, incluindo carcinomas salivares. Nestes, o risco de metástases em linfonodos é variável e fortemente associado com o tipo histológico do tumor. O objetivo do presente estudo foi avaliar a densidade vascular linfática (DVL) e a expressão dos fatores de crescimento linfangiogênicos das células tumorais em diferentes tipos de carcinomas salivares subdivididos de acordo com o risco para metástases em linfonodos. Em 15 tumores de alto risco (indiferenciado, mucoepidermóide de alto grau e carcinomas de ducto salivar) e 60 de baixo/moderado risco (adenóide cístico, mucoepidermoide de grau baixo/intermediário, célula acinar, mioepitelial, carcinoma mioepitelial-epitelial e carcinoma polimórfico de baixo grau) foram examinadas as expressões do fator de crescimento do endotélio vascular-C (VEGF-C), fator de crescimento do hepatócito (HGF) e D2-40 (para avaliação da LVD). Nenhuma diferença significativa foi encontrada entre carcinomas de alto e baixo/moderado risco, em relação a DVL e a expressão de VEGF-C ou HGF. Além disso, a expressão destas proteínas não teve correlação com a DLV. Invasão vascular linfática foi encontrada principalmente em carcinomas de alto risco. A DLV intratumoral foi significativamente mais baixa do que a peritumoral, independentemente do risco para metástases e do sítio primário da lesão. Em conclusão, os tipos histológicos dos carcinomas salivares que estão associados com alto risco para metástase em linfonodos não apresentam aumento da DVL ou expressão do VEGF-C e HGF. A maior tendência para metástases nestes carcinomas parece estar relacionada com a sua capacidade para invadir os vasos linfáticos. Estudos adicionais sobre a interação das células tumorais com as células endoteliais são necessários para aumentar a nossa compreensão sobre o potencial metastático dos carcinomas salivares / Abstract: Nodal metastasis is an important prognostic indicator in head and neck cancers, including salivary carcinomas. In these, the risk for lymph node metastasis is variable and strongly associated with the tumor histologic type. The aim of the current study was to evaluate the lymphatic vessel density (LVD) and expressions of lymphangiogenic growth factors by tumor cells in different histologic types of salivary carcinomas subdivided according to the risk for nodal metastasis. In 15 high-risk (undifferentiated, high-grade mucoepidermoid and salivary duct carcinomas) and 60 low/moderate-risk tumors (adenoid cystic, low/intermediate-grade mucoepidermoid, acinic cell, myoepithelial, epithelial-myoepithelial and polymorphic low-grade carcinomas) the expressions of vascular endothelial growth factor-C (VEGF-C), hepatocyte growth factor (HGF) and D2-40 (for assessing LVD) were examined. No significant differences were encountered between high and low/moderate/-risk carcinomas regarding LVD and VEGF-C or HGF expressions. Furthermore, the expression of these proteins did not correlate with LVD. Lymphatic vascular invasion was mainly found in high-risk carcinomas. Intratumoral LVD was significantly lower than peritumoral, regardless of the risk for metastasis and primary site of the lesion. The histologic types of salivary carcinomas which are associated with high-risk for nodal metastasis do not present increased LVD or VEGF-C and HGF expressions. The greater tendency for metastasis in these carcinomas seems to be related to their capacity to invade lymph vessels. Further studies on tumor cell interactions with lymphatic endothelial cells are needed to improve our understanding of the metastatic potential of salivary carcinomas / Mestrado / Anatomia Patologica / Mestre em Ciências Médicas

Com o intuito de investigar se a hipóxia representa um dos desencadeadores da regressão luteínica em cadelas não prenhes, o presente estudo foi delineado para analisar a expressão do fator transcricional indutível por hipóxia HIF1A e a de seus genes-alvo relacionados à angiogênese, como o fator de crescimento endotelial vascular (VEGFA) e à captação de glicose, como as proteínas transportadoras facilitadoras GLUT1/SLC2A1 e GLUT4/SLC2A4 no corpo lúteo canino ao longo do diestro (dias 10 a 70 após a ovulação). Para tal, utilizou-se imuno-histoquímica e western blotting para localizar e quantificar as proteínas do HIF1A, GLUT1 e GLUT4 e PCR em tempo real para quantificar a expressão do RNAm de HIF1A, SLC2A1, SLC2A4, VEGFA, FLT1 e KDR. Além disso, células luteínicas nas fases inicial (dia 10), média (dia 30) e final (dia 60) foram submetidas ao tratamento com cloreto de cobalto (CoCl2) a 500 &micro;M para avaliar os efeitos da hipóxia sobre a expressão gênica dos fatores acima citados, bem como sobre a produção de progesterona e 17&beta;-estradiol. Nossos resultados demonstraram que o HIF1A é expresso pelo corpo lúteo canino de maneira tempo-dependente ao longo do diestro, e que a expressão de seu RNAm está diretamente correlacionada a expressão gênica de SLC2A1, SLC2A4, VEGFA, FLT1 e KDR e com as concentrações de progesterona periférica. No cultivo primário de células luteínicas, a hipóxia induzida pelo CoCl2 diminuiu a produção de progesterona e de 17&beta;-estradiol e estimulou significativamente a expressão de HIF1A, SLC2A1, SLC2A4 e VEGFA. Esses resultados sugerem que o HIF1A constitui um dos fatores regulatórios da função do corpo lúteo canino participando da modulação de processos como esteroidogêne, angiogênese e da captação de glicose, atuando como fator luteolítico. / This study was designed to investigate if hypoxia is one of the triggers of luteal regression in non-pregnant bitches. For that, we analyzed the hypoxia- inducible factor (HIF1A) expression as well as the expression of its target genes related to angiogenesis (vascular endothelial growth factor VEGFA) and to glucose uptake (glucose transporters GLUT/SLC2A 1 and 4) in canine corpus luteum throughout diestrus (days 10 to 70 after ovulation). We used immunohistochemistry and western blotting to localize and quantify the protein expression of HIF1A, GLUT1 and GLUT4, respectively, and real time PCR to analyze HIF1A, SLC2A1, SLC2A4, VEGFA, FLT1 and KDR gene expression. Moreover, luteal cells from early (day 10), mid (day 30) and late luteal phase (day 60) were submitted to 500 &micro;M cobalt chloride (CoCl2) treatment to verify hypoxia effects on gene expression of the above cited genes and on progesterone and 17&beta;-estradiol production. Our results showed that luteal cells expressed HIF1A in a time-dependent manner over diestrus and that its expression was directly correlated to both SLC2A1, SLC2A4, VEGFA, FLT1 and KDR gene expression and progesterone production. The protein expression of the studied genes also changed over diestrus and was correlated with the respective gene expression. In primary luteal cells culture, cobalt chloride-induced hypoxia downregulated progesterone and 17&beta;-estradiol production, but upregulated HIF1A, SLC2A1, SLC2A4 and VEGFA gene expression. These findings suggest that HIF1A is one of the factors regulating canine luteal function by modulating important process as steroidogenesis, angiogenesis and glucose uptake, acting as a pro-survival factor.

O sistema linfoide é composto de órgãos linfoides primários e secundários. O timo é um órgão linfoide primário responsável pela maturação, diferenciação e seleção da linhagem linfocitária do tipo T que é responsavel pela imunidade celular do individuo. Para cumprir estas funções, o timo possui uma disposição peculiar das suas células epiteliais morfologicamente distintas e de suas estruturas vasculares. Seus vasos sanguíneos possuem um papel na oxigenação tecidual e no processo de migração das células precursoras de linfócitos T para o interior do parênquima tímico e por isso apresentam uma arquitetura típica caracterizada por vasos de grande calibre, localizados na junção cortico-medular e uma fina rede de ramos e anastomoses que se estendem para o córtex. Este processo de estruturação e arquitetura vascular ainda possui sua base molecular desconhecida, assim como os mecanismos que provocam a involução do órgão. O VEGF é um fator angiogênico que atua na formação vascular e na modulação de funções relacionadas à vascularização, sendo um importante marcador da angiogênese. A fim de se melhor compreender o comportamento vascular na formação e involução tímica, propôs-se avaliar a expressão gênica e proteica deste fator durante fases de desenvolvimento e involução do órgão, além da quantificação da vascularização do timo pela técnica estereológica, análise do parênquima tímico pela técnica de microscopia eletrônica de varredura e análise dos tipos celulares presentes em cada estágio etário. Para tal utilizou-se amostras de timo de gato em quatro estágios de desenvolvimento fetal (35, 45, 55, 65), e dois estágios pós-natal (6 meses e 1 ano) para a realização da imuno-histoquímica, PCR em tempo real e MEV,e para a técnica estereológica 2 estágios pós-natal (6 meses e 1 ano). Na microscopia eletrônica de varredura foram observados os timócitos de diferentes tamanhos, em estágios de maturação distintos. As proteinas do VEGF-A e dos receptores Fit-1 e KDR foram identificadas no timo de gatos em todas as fases do desenvolvimento foram localizadas no citoplasma de células epiteliais e no interior dos corpúsculos tímicos. A expressão do mRNA no período de 1 ano de idade a expressão do mRNA do VEGF e seus receptores tem um aumento significativo, coincidindo com a diminuição do Nvasc e do Nv(vasc) podendo causar um estado de hipóxia no órgão levando a um aumento compensatório de sistema VEGF. A curva de crescimento vascular obedece a um padrão de desenvolvimento e involuçãio do órgão. / The lymphoid system is composed by primary and secondary lymphoid organs. The thymus is a primary lymphoid organ responsible for maturation, differentiation and selection of the lymphoid T cell lineage that is responsible for cellular immunity. To accomplish these functions has a peculiar arrangement with morphologically distinct epithelial cells and vascular structures. The blood vessels have a role in tissue oxygentation and the migration of T cells into the thymic parenchyma, therefore they presents large vessels in cortico-medullary junction and a fine network branches to the cortex. This process has its molecular basis unknown as well as the involution process of the thymus. VEGF is an angiogenic factor that plays a role in the formation and modulation of vascular functions, being an important marker of angiogenesis. We proposed to evaluate the gene and protein of VEGF during the thymus development and involution, stereological quantification and scanning electronic microscopy. Samples of cat´s thymus from 35, 45, 55, 65 days of development and 6 months and 1 year of age. In scanning electronic microscopy different stages maturation thymocytes were observed. Protein expression of VEGF and its receptors were identified in all development stages in epithelial cells, endothelial cells and thymic corpuscles. The VEGF mRNA expression and its receptors in 1 year old animals was significantly increased, coinciding with the decreasing Nvasc and the Nv(vasc) causing a hypoxic condition in the thymus resulting in a compensatory increase of VEGF system. The vascular growth curve follows a pattern of development and involution of the organ.

A formação de novos vasos sanguíneos é fundamental para o crescimento tumoral e a disseminação metastática, sendo o fator de crescimento endotelial vascular (VEGF) uma das chaves reguladoras deste processo. O objetivo do presente estudo foi avaliar a expressão imunohistoquímica de VEGF nos hemangiossarcomas e hemangiomas esplênicos, e rever a prevalência das demais afecções esplênicas através da análise retrospectiva do diagnóstico histopatológico de cães submetidos à esplenectomia. Os resultados foram confrontados com os exames laboratoriais, as manifestações clínicas, a presença de arritmias cardíacas e de hemoperitôneo. Participaram do estudo retrospectivo 109 cães atendidos no Serviço de Cirurgia de Pequenos Animais do Hospital Veterinário da Faculdade de Medicina Veterinária e Zootecnia da Universidade de São Paulo, entre os anos de 2002 e 2009. A média de idade foi de 10 anos (± 3), não foi observado predileção sexual. Cães sem raça definida foram os mais acometidos, com peso médio de 22 kg (± 13). Cinqüenta e dois por cento (57/109) dos animais foram esplenectomizados devido a afecções não neoplásicas, enquanto que 48% (52/109), por neoplasias esplênicas. Dentre estes, o diagnóstico mais freqüente foi o hemangiossarcoma, acometendo 28 (54%) animais. Os sintomas mais freqüentes foram disorexia, apatia e emese. Cães com neoplasias malignas apresentaram níveis de hematócrito e hemácias significativamente menores que os acometidos por massas benignas. Do mesmo modo, a presença de hemoperitôneo, secundário à ruptura esplênica, correlacionou-se significativamente com a presença de neoplasia maligna. Arritmias cardíacas não foram fatores preditivos para a diferenciação da esplenomegalia. A avaliação imunohistoquímica da expressão tecidual de VEGF foi realizada em 23 hemangiossarcomas e 7 hemangiomas, revelando-se significativamente maior nas neoplasias malignas. Tal resultado sugere que a expressão deste fator pode estar relacionada à proliferação maligna observada nos hemangiossarcomas. / New blood vessel formation is a fundamental event in the process of tumor growth and metastatic dissemination, being the vascular endothelial growth factor (VEGF) one of the key regulators of this process. The aim of this study was evaluate the VEGF immunohistochemical expression in splenic hemangiosarcomas and hemangiomas, and review the prevalence of canine splenic disorders through retrospective analysis of histological diagnosis after splenectomy. The results were confronted with laboratory findings, clinical signs and presence of cardiac arrhythmia and hemoperitoneum. A hundred nine dogs were included in the retrospective study at Veterinary Hospital of School of Veterinary Medicine, University of Sao Paulo, between 2002 and 2009. The average age was 10 year ± 3, without sexual predilection. Mix breeds were the most frequent, and average weigh was 22kg ± 13. Overall, 52% (57/109) of dogs were splenectomized for nonneoplastic disease, although 48% (52/109) were splenectomized for neoplasia. Among these dogs the most common diagnosis was hemangiossarcoma (28 dogs, 54%). Frequently clinical signs included anorexia, lethargy and vomiting. Dogs with malignant neoplasia had significantly lower red blood cells counts and packed cell volume compared with values for dogs with benign masses. Similarly, hemoperitoneum secondary to splenic rupture had a significant correlation with malignant tumor. Cardiac arrhythmia was not useful in differentiating dogs with splenomegaly. Expression of vascular endothelial growth factor was made by immunohistochemical analyses in 23 hemangiosarcomas and 7 hemangiomas being significantly higher in malignant tumor. These data suggest that VEGF expression may contribute to malignant proliferation of hemangiossarcoma.

L’œdème maculaire est une complication majeure de nombreuses pathologies rétiniennes induisant la cécité. Les traitements actuels ne sont pas curatifs. Ce sont des injections intraoculaires de corticostéroïdes et d'anti-VEGF. Les mécanismes d'action de ces médicaments sont mal connus dans l'œil car ces thérapies ont été initialement développées pour des pathologies non-oculaires (tels que l'asthme et les maladies auto-immunes pour les corticostéroïdes et les cancers pour certains anti-VEGF). De plus, les effets bénéfiques de ces molécules sont contrebalancés par des effets secondaires graves (glaucomes et cataractes pour les corticostéroïdes) et la résistance au traitement. Le projet vise à élucider les mécanismes d'action oculaires des corticostéroïdes et anti-VEGF; dans le but d'identifier de nouvelles cibles thérapeutiques pour le traitement de l’œdème maculaire. Ce travail a porté sur : 1) La compréhension des mécanismes des corticostéroïdes et de leurs récepteurs (le récepteur aux glucocorticoïdes ou GR et le récepteur aux minéralocorticoïdes ou MR) suite à l’injection intravitréene de corticostéroïdes ou d’aldostérone chez le rat. Nous avons ainsi : -1.1. Identifier les protéines partenaires du GR et du MR avant et après traitements par une approche protéomique (immunoprécipitations endogènes suivies d’une analyse par spectrométrie de masse). -1.2. Identification les gènes cibles dont l'expression est modulée par les corticostéroïdes ou l’aldostérone par ARN-sequencing. 2) L'identification des mécanismes d’action des aux anti-VEGFs et leur comparaison avec des molécules de même nature physico-chimique. 3) L’identification des gènes différentiellement exprimés entre la rétine périphérique et la macula (zone d’acuité visuelle susceptible à la formation d’œdèmes) chez le singe (modèle qui possède, comme l’homme, une macula). Ceci afin de comprendre pourquoi la macula est particulièrement sensible. 4) L’analyse et la comparaison de ces différents traitements. Ces études ont permis d’identifier les cofacteurs des récepteurs aux corticostéroïdes, ainsi que la dynamique de leurs interactions avant et après traitement à la corticostérone et à l’aldostérone; ainsi que les gènes dont l’expression est régulée par les corticostéroïdes et les anti-VEGF. L’analyse croisée des données, des analyses bioinformatiques ainsi que l’étude bibliographique des protéines et gènes identifiés nous ont permis d’établir une liste restreinte de cibles potentielles des traitements anti-œdémateux, dans le but final de potentialiser l’effet de ces traitements, trop souvent associés à des effets secondaires qui limitent considérablement leur(s) action(s) bénéfique(s) sur la fonction visuelle dans le traitement de l’œdème maculaire. / Macular Edema is a major complication of numerous retinal pathologies that lead the blindness. The available treatments (intra-ocular injection of corticosteroids and anti-VEGF) do not cure this disease. The ocular mechanisms of action of these drugs are not very well understood. In fact, these molecules have been initially developed for non-ocular pathologies, such as asthma, auto-immune diseases (for corticosteroid) and cancers (for anti-VEGF). In addition, the beneficial effects of these drugs are counteracted by their side effects (cataracts and glaucoma for corticosteroids) as well as resistance to treatment. The project aims at unraveling the ocular mechanisms of action of corticosteroids and anti-VEGF; in order to identify new therapeutic targets for the treatment of macular edema. The project focused on: 1) The understanding of the mechanisms of the corticosteroids and their receptors after an intravitreal injection of Corticosterone or Aldosterone in the rat model. We therefore: 1.1. Identified the partner proteins of the glucocorticoid and mineralocorticoid receptors before and after treatment, using a proteomic approach. 1.2. Identified the target genes which expression is modulated by the corticosteroid using the RNA-Sequencing technique. 2) The identification of the mechanisms of action of anti-VEGF molecules and their comparison with molecules that have similar physico-chemical structure. 3) The identification of differentially expressed genes between the retina and the macula in the monkey model. This aimed at understanding why the macula is particularly sensitive to edemas. 4) The analysis and comparison of these treatments. We were able to identify co-factors for corticosteroids receptors as well as the dynamics of these interactions (before and after treatment), as well as the genes which expression is regulated by the corticosteroids or anti-VEGF. The analysis of the bio-informatic data as well as the bibliographic study of the identified proteins and genes allowed us to establish a list of partiMacularly interesting genes that are potentially therapeutic targets for the treatment of macular edema.

L’irinotecan est un agent anticancéreux majeur utilisé dans le traitement du cancer du côlon où il agit à la fois comme un agent causant des dommages à l’ADN et un inhibiteur de l’angiogenèse. L’activité de l’irinotécan dans les cancers colorectaux est limitée par le développement d’une résistance acquise au médicament. Le but de ce travail est de caractériser l’influence d’une exposition prolongée à l’irinotécan sur la biologie des cellules cancéreuses colorectales in vivo et in vitro. Résultats majeurs : Nous avons exposé les cellules de cancer colorectal, HT-29 (LOH) et HCT-116 (MSI), au SN-38 (le métabolite actif de l'irinotécan) pendant un an. Ceci a permis de sélectionner des cellules résistances à l’irinotécan et ceci de manière stable. Une caractérisation plus approfondie a révélé que la résistance acquise à l’irinotécan était accompagnée d’altérations multiples, y compris la diminution de la formation de complexes clivables et de cassures double brins. Nos études ont montré des changements inattendus dans la distribution du cycle cellulaire et la vitesse de croissance des deux lignées résistantes. La pertinence in vivo de nos modèles cellulaires a ensuite été confirmée dans des modèles de xénogreffe.D’autres résultats basé sur l’inhibition de l’angiogenèse montrent que l'exposition prolongée à l’irinotécan est accompagnée d’une modification majeure de la voie HIF, VEGF / VEGFR dans les cellules tumorales. Ces travaux ont permis d’identifier des modifications biologiques dans les cellules résistantes susceptibles de les rendre plus résistantes ou sensibles à d’autres classes d’agents anticancéreux afin de proposer de nouvelles combinaisons thérapeutiques.Ce travail est financé par l’Institut National du Cancer / Colorectal cancer (CRC) is one of the most common tumors and a leading cause of cancer death worldwide. Until recently, fluorouracil in combination with leucovorin was the only effective systemic treatment for CRC. During the last few years, four new treatments have been approved for advanced CRC including the topoisomerase I (topo I) inhibitor irinotecan, the epidermal growth factor receptor (EGFR)-directed monoclonal antibody cetuximab and the vascular endothelial growth factor (VEGF)-directed monoclonal antibody bevacizumab. Unfortunetly their clinical activity is often limited by the development of resistance. Several lines of experimental evidence suggest a functional interaction between topo I and EGFR. Furthermore, topo I can regulate hypoxia-inducible factor 1 alpha (HIF-1alpha), a key regulator of cellular response to hypoxia, leading to VEGF production.We propose to study the EGFR-signaling pathway on the cellular response to cytotoxic agents with the topo I inhibitor irinotecan/SN-38 as model.Resistant cells were obtained by culturing HT-29 and HCT-116 cells in increasing concentrations of irinotecan. After obtaining, their drug resistance was 5 to 25 times increased compared to the parental cells. We first showed that the proliferation of the two resistant cell lines was slower than the sensitive ones. We were able to confirm it with different in vitro and in vivo experiment. It is interesting to notice that topo I expression was unchanged in our resistant cell lines. We then demonstrated that the resistant cells are less affected by the formation of DNA strand breaks (led by SN38) than the sensitive ones. Moreover, the EGFR expression is increased in the resistant cell lines. We also shown by western blot and ELISA that resistance development comes along with an increase of VEGF.Our data should provide important clues on the irinotecan acquired resistant cells and should help to set up new combinations for colorecal cancer treatment.

L’angiogenèse étant un processus limité dans des conditions physiologiques et un processus clé dans la croissance tumorale, elle est devenue une cible thérapeutique prometteuse. La neuropiline-1 (Np1) est un corécepteur du VEGF, qui est le facteur pro-angiogénique le mieux décrit jusqu’à présent. Dans cette thèse, nous nous intéressons à la modélisation du ligand 47, une molécule active expérimentalement, en vue de l’amarrer dans la neuropiline-1. En raison de sa flexibilité conformationnelle, ce ligand pourrait en effet adopter une conformation étendue, comme la tuftsine, un ligand naturel de Np1, ou une conformation repliée. Une étape préliminaire essentielle, avant l'exploration de la complexation du lig-47 a Np1, est l'étude de sa flexibilité conformationnelle. Il est en effet impératif de s'assurer que les interactions intra-moleculaires (conformationnelles) dans le lig-47 sont calculées a une precision comparable a celles de ses interactions intermoléculaires avec Np1. Un écueil important tient au caractère conjugue du lig-47. Les quatre fragments constitutifs de cette molecule sont tous aromatiques ou conjugues, et sont tous connectes par des atomes insaturés. [...] Nous avons, dans une première étape, construit la molécule en quatre fragments : le benzimidazole, le méthylbenzène, le benzodioxane et le carboxythiourée (CTU). Nous avons approché ces quatre fragments par une molécule d’eau afin de calibrer les rayons de Van de Waals effectifs impliqués dans les contributions d’énergies électrostatique et de répulsion. L’anisotropie ayant été assurée, nous avons cherché à reproduire la conjugaison, par la calibration des barrières de torsion V0 primaires (n=1) et binaires (n=2). Nous obtenons des accords très satisfaisants entre les courbes conformationnelles obtenues avec SIBFA et celles obtenues par des calculs de chimie quantique (QC). Nous avons ensuite effectué des minimisations de l'énergie SIBFA en partant des minima des six courbes conformationnelles. Afin d'évaluer la transférabilité de la méthode, nous avons comparé les stabilités relatives de ces minima par des calculs QC ponctuels. Or les différences d'énergie séparant le minimum « global » des minima locaux se sont avérées sous-estimées par rapport aux calculs QC. Ces résultats nous ont amenés à envisager des façons différentes de représenter le fragment CTU. La possibilité la plus évidente consiste à le séparer en deux sous-fragments amide et thioamide. Les effets de la conjugaison et de la transférabilite des multipôles et polarisabilités sont ainsi perdus mais pourraient être compensés par la prise en compte explicite de l’énergie de polarisation des fragments amide et thioamide. Avec cette approche, la recalibration des rayons effectifs a permis de préserver des accords convenables avec les calculs quantiques pour l'approche des atomes du CTU par une molécule d'eau sonde. Les courbes conformationnelles reproduisent de près les courbes QC avec une recalibration minimale. Les minima de ces courbes ont été a nouveau minimisés en SIBFA, conduisant a des structures néanmoins très proches des minima correspondants de l'approche précédente avec un CTU construit d'un seul tenant. Mais à présent, les différences d'énergie séparant le minimum global des minima locaux sont très voisine de celles trouvées en QC. De plus, l'évolution des courbes conformationnelles en fonction de la structure considérée s'est avérée régie par l'énergie de polarisation. Par ailleurs, nous avons obtenu des résultats satisfaisants lors de l’amarrage de la tuftsine dans Np1. Ces résultats s'avèrent suffisamment probants pour permettre d'envisager à présent une étude détaillée des modes d'interaction du lig-47 avec Np-1. / Angiogenesis is a limited process in physiological conditions and a key process in tumor growth. Hence, it has become a promising therapeutic target. The neuropilin-1 (Np1) is a co-receptor for VEGF, which is today the best known pro-angiogenic factor. This manuscript deals with the molecular modelling of the ligand 47 (lig47), an experimentally active molecule, in order to dock it into Np1. Due to its conformational flexibility, this ligand could adopt and extended conformation such as tuftsin, a natural ligand, does in its complex with Np1, or a folded conformation. An essential preliminary step, before the exploration of the complexation of lig47 with Np1 is the study of its conformational flexibility. Indeed it must be ensured that the intramolecular (conformational) interactions are calculated with precision compared with the calculations of the interaction energies with Np1. An important issue comes from the polyconjugaison of the lig47. [...] We probed these four fragments with a water molecule in order to calibrate the effective Van der Waals radii implicated in electrostatic and repulsion contributions. Once the anisotropy was reproduced, we looked for reproducing the effect of the conjugaison on torsional barriers. We hence calibrated primary (n=1) and binary (n=2) barriers. We obtained very satisfactory agreements between the conformational curves obtained with SIBFA and those obtained with quantum chemistry (QC) calculations. Then we performed energy minimizations of SIBFA energy of the minima of the ix conformational curves. In order to evaluate the transferability of the method, we compared the relative stabilities of these minima with single-point QC calculations. But the differences of energy between the global minimum and local minima were underestimated in comparison with QC calculations. These results lead us to consider different ways of representing CTU. The more evident way consists in separating it in two fragments amide and thioamide. The effects of the conjugaison and the transferability of the multipoles and the polarisabilities are lost but could be compensated by the explicit consideration of the polarization energy between the amide and thioamide fragments. With this approach, the recalibration of the effective radii permitted to preserve good agreements with the QC calculations when probing the CTU by a water molecule. The conformational curves reproduce the QC curves after a minimal recalibration. The minima of these curves were then re-minimized with SIBFA, leading to structures close to those obtained with the first representation. But now, the differences of energy between the global minimum and the local minima are very close to those obtained in QC. Moreover, the evolution of the conformational curves as function of the number of the structure is ruled by the polarization energy. Otherwise, we obtained satisfactory results when we docked the tuftsin in Np1. These results will allow us to consider a detailed study of the interaction between lig47 et Np1.

Le but des travaux est de caractériser l’influence de la signalisation VEGF, en particulier la signalisation autocrine VEGF, sur la biologie et la sensibilité/résistance aux médicaments anticancéreux de cellules de cancer colorectal. Nous avons souhaité caractériser l’impact de la signalisation autocrine VEGF dans des modèles de CRC avec une résistance naturelle au bevacizumab, un anticorps anti-VEGF. Bien que ce composé soit actif dans le CRC, une sous population de patients ne répondent pas au traitement. Nos résultats montrent une sur régulation de la voie autocrine HIF-VEGF-VEGFR en réponse à une exposition prolongée au bevacizumab dans les cellules bevacizumab résistantes. Si la résistance à cet anticorps est bien établie, d’autres inhibiteur de la voie VEGF restent actifs (comme la petite molécule ciblée nintedanib) et peuvent inhiber la voie mTOR. La signalisation VEGF autocrine joue un rôle dans la survie de cellules de CRC. Chez les sujets résistants au bevacizumab, il serait intéressant d’introduire le nintedanib seul ou en combinaison pour accentuer l’inhibition angiogénique. Une autre combinaison d’agents (anti VEGF(R) et anti EGFR) a montré une efficacité dans des modèles de CRC en préclinique. La combinaison du bevacizumab et d’une petite molécule ciblant EGFR (erlotinib) a montré une plus grande efficacité que le bevacizumab seul dans des modèles de CRC indépendamment du statut KRAS. Le bevacizumab induit une activation de la voie de survie EGFR dans les cellules tumorales et dans les cellules endothéliales associées à la tumeur. Cette activation se trouve diminuée avec l’introduction de l’erlotinib. Les résultats indiquent que la combinaison du bevacizumab et de l’erlotinib sont plus actif en thérapie de maintenance que le bevacizumab seul, même pour les patients mutés KRAS. Ces résultats ont mené à l’étude clinique positive GERCOR phase III DREAM dans le cancer du côlon métastatique. / The aim of the work is to characterize the influence of VEGF signaling , especially autocrine VEGF signaling , the biology and susceptibility / resistance to anticancer drugs of colorectal cancer cells. We wished to characterize the impact of the autocrine VEGF signaling in CRC models with natural resistance to bevacizumab , an anti -VEGF antibody. Although this compound is active in the CRC, a subpopulation of patients do not respond to treatment. Our results show an autocrine regulatory pathway HIF- VEGF- VEGFR in response to prolonged exposure to bevacizumab in bevacizumab resistant cells. If the resistance to the antibody is established, other inhibitos of VEGF pathway remain active (such as small molecule nintedanib ) and can inhibit the mTOR pathway. Autocrine VEGF signaling plays a role in CRC cell survival. In subjects resistant to bevacizumab, it would be interesting to introduce the nintedanib alone or in combination to enhance the angiogenic inhibition. Another combination of targeted agents ( anti-VEGF (R) and anti EGFR) has shown efficacy in preclinical models of CRC. The combination of bevacizumab and a small molecule targeting EGFR (erlotinib) showed greater efficacy than bevacizumab alone in CRC models regardless of KRAS status. Bevacizumab induces activation of the EGFR survival pathway in tumor cells and in endothelial cells associated with the tumor. This activation is decreased with the introduction of erlotinib. The results indicate that the combination of bevacizumab and erlotinib are more active in maintenance therapy than bevacizumab alone, even for patients mutated KRAS . These findings led to the positive Phase III clinical study GERCOR DREAM in metastatic colon cancer.